London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that its third annual pharmacogenetic conference will feature top-level presentations from players in all parts of the healthcare chain. To be held on 8-9th November 2011, in Windsor, UK, the theme for this year's conference is 'Stratified Medicine: Making It Happen'. Topical issues will be discussed and debated with presentations from academia, the FDA, EMA, AstraZeneca, Novartis, Quintiles, Medco and the Wolfson Centre for Personalised Medicine, UK.
The conference is focused on how stratified medicine is affecting a range of activities, from reimbursement, prescribing and regulatory approval, to study design, use of biomarkers, data interpretation and the co-development of drugs and diagnostics. Consideration will also be given to some of the ethical issues, with a discussion from Professor Jonathan Wolff, member of the Nuffield Council on Bioethics Working Party for its recent report, 'Medical profiling and online medicine: the ethics of 'personalised healthcare' in a consumer age'.
Dr Elizabeth Foot, CEO of London Genetics, said, 'We are delighted at how the agenda for London Genetics' third annual pharmacogenetic conference is developing, and are looking forward to hearing about the latest thinking in this rapidly evolving area. There was very positive feedback on the quality of the talks and interactions at last year's conference, and we expect the 2011 event to be just as successful for London Genetics, which has recently signed a research collaboration with an undisclosed pharmaceutical company.'
UK's drug payment disclosure system fails to protect patients and public trust